Cognitive MRI-Ultrasound Fusion Transperineal Targeted Biopsy and Biopsy in Detection of Prostate Cancer

A study aimed to investigate the diagnostic efficiency of a template for cognitive MRI-ultrasound fusion transperineal targeted plus randomized biopsy in detecting prostate cancer (PCa). The findings were published in World Journal of Clinical Cases.

Researchers retrospectively assessed data from 127 patients with an increasing prostate-specific antigen (PSA) level but less than 20 ng/mL and at least one lesion suspicious for PCa on MRI from December 2015 to June 2018. The population of interest all underwent cognitive fusion transperineal template-guided targeted biopsy followed by randomized biopsy outside the targeted area.

According to the results, PCa was detected in approximately 52% of patients, and 56 cases presented clinically significant PCa. The results showed that cognitive fusion targeted biopsy alone detected in around 46% of PCa cases, particularly in those with clinically significant PCa, and just over 8% of cases with clinically insignificant PCa.

A randomized biopsy detected seven cases of PCa negative on targeted biopsy, and four cases had clinically significant PCa, the researchers noted. PSA density (odds ratio [OR] = 1.008, 95% confidence interval [CI] 1.003-1.012, P = 0.001; OR = 1.006, 95% CI 1.002-1.010, P = 0.004) and Prostate Imaging-Reporting and Data System (PI-RADS) scores (both P <0.001) were independently associated with the results of cognitive fusion targeted biopsy combined with randomized biopsy and targeted biopsy alone.

“This single-centered study proposed a feasible template for cognitive MRI-ultrasound fusion transperineal targeted plus randomized biopsy. Patients with higher PSA density and PI-RADS scores were more likely to be diagnosed with PCa,” the researchers concluded.